AU2016280280B2 - Improved formulations of deferasirox and methods of making the same - Google Patents

Improved formulations of deferasirox and methods of making the same Download PDF

Info

Publication number
AU2016280280B2
AU2016280280B2 AU2016280280A AU2016280280A AU2016280280B2 AU 2016280280 B2 AU2016280280 B2 AU 2016280280B2 AU 2016280280 A AU2016280280 A AU 2016280280A AU 2016280280 A AU2016280280 A AU 2016280280A AU 2016280280 B2 AU2016280280 B2 AU 2016280280B2
Authority
AU
Australia
Prior art keywords
dfx
composition
poly
pharmaceutical composition
deferasirox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016280280A
Other languages
English (en)
Other versions
AU2016280280A1 (en
Inventor
Justin M. Keen
Sandra U. Kucera
Dave A. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AustinPx LLC
Original Assignee
AustinPx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AustinPx LLC filed Critical AustinPx LLC
Publication of AU2016280280A1 publication Critical patent/AU2016280280A1/en
Application granted granted Critical
Publication of AU2016280280B2 publication Critical patent/AU2016280280B2/en
Priority to AU2021277731A priority Critical patent/AU2021277731B2/en
Assigned to AustinPx, LLC reassignment AustinPx, LLC Request to Amend Deed and Register Assignors: DISPERSOL TECHNOLOGIES, LLC
Priority to AU2024202528A priority patent/AU2024202528B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016280280A 2015-06-17 2016-06-17 Improved formulations of deferasirox and methods of making the same Active AU2016280280B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021277731A AU2021277731B2 (en) 2015-06-17 2021-12-02 Improved formulations of deferasirox and methods of making the same
AU2024202528A AU2024202528B2 (en) 2015-06-17 2024-04-17 Improved formulations of deferasirox and methods of making the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180998P 2015-06-17 2015-06-17
US62/180,998 2015-06-17
PCT/US2016/038089 WO2016205658A1 (en) 2015-06-17 2016-06-17 Improved formulations of deferasirox and methods of making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021277731A Division AU2021277731B2 (en) 2015-06-17 2021-12-02 Improved formulations of deferasirox and methods of making the same

Publications (2)

Publication Number Publication Date
AU2016280280A1 AU2016280280A1 (en) 2018-01-04
AU2016280280B2 true AU2016280280B2 (en) 2021-09-02

Family

ID=57546755

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016280280A Active AU2016280280B2 (en) 2015-06-17 2016-06-17 Improved formulations of deferasirox and methods of making the same
AU2021277731A Active AU2021277731B2 (en) 2015-06-17 2021-12-02 Improved formulations of deferasirox and methods of making the same
AU2024202528A Active AU2024202528B2 (en) 2015-06-17 2024-04-17 Improved formulations of deferasirox and methods of making the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021277731A Active AU2021277731B2 (en) 2015-06-17 2021-12-02 Improved formulations of deferasirox and methods of making the same
AU2024202528A Active AU2024202528B2 (en) 2015-06-17 2024-04-17 Improved formulations of deferasirox and methods of making the same

Country Status (10)

Country Link
US (4) US10265301B2 (cg-RX-API-DMAC10.html)
EP (1) EP3310354B1 (cg-RX-API-DMAC10.html)
JP (1) JP2018517734A (cg-RX-API-DMAC10.html)
CN (1) CN107847490A (cg-RX-API-DMAC10.html)
AU (3) AU2016280280B2 (cg-RX-API-DMAC10.html)
CA (1) CA2989145C (cg-RX-API-DMAC10.html)
HK (1) HK1254608A1 (cg-RX-API-DMAC10.html)
IL (1) IL256322B (cg-RX-API-DMAC10.html)
MA (1) MA43271A (cg-RX-API-DMAC10.html)
WO (1) WO2016205658A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103290106B (zh) 2007-12-05 2015-07-29 考利达基因组股份有限公司 测序反应中碱基的有效确定
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CN102459592B (zh) 2009-06-15 2017-04-05 考利达基因组股份有限公司 用于长片段阅读测序的方法和组合物
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
WO2020061474A1 (en) * 2018-09-20 2020-03-26 Tautona Group Ip Holding Company, L.L.C. Iron chelating compounds for treating aesthetic skin conditions
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN112870361A (zh) * 2021-01-28 2021-06-01 重庆医科大学 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
CN114994205B (zh) * 2022-05-30 2023-03-28 上海奥科达医药科技股份有限公司 地拉罗司颗粒剂中相关杂质的检测方法
AU2025207356A1 (en) 2024-01-11 2026-08-06 Minneamrita Therapeutics Llc Triptolide formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120245361A1 (en) * 2009-12-07 2012-09-27 Mapi Pharma Hk Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
US20130142871A1 (en) * 2010-07-08 2013-06-06 Ratiopharm Gmbh Oral dosage form of deferasirox
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
WO2014181108A1 (en) * 2013-05-10 2014-11-13 Cipla Limited Low dose pharmaceutical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
NZ567155A (en) * 2005-10-19 2010-06-25 Novartis Ag Dispersible tablets comprising deferasirox
WO2009026461A2 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
WO2012025935A2 (en) * 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
PE20140166A1 (es) 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
HUE036921T2 (hu) 2013-03-08 2018-08-28 Novartis Ag Orális deferasirox készítmények

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120245361A1 (en) * 2009-12-07 2012-09-27 Mapi Pharma Hk Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
US20130142871A1 (en) * 2010-07-08 2013-06-06 Ratiopharm Gmbh Oral dosage form of deferasirox
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
WO2014181108A1 (en) * 2013-05-10 2014-11-13 Cipla Limited Low dose pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Guy Van den Mooter, "The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate", Drug Discovery Today: Technologies, 2012, vol. 9, no.1, e79-e85 *

Also Published As

Publication number Publication date
US10265301B2 (en) 2019-04-23
EP3310354B1 (en) 2026-02-25
AU2021277731A1 (en) 2021-12-23
US20240091201A1 (en) 2024-03-21
IL256322A (en) 2018-02-28
US11878005B2 (en) 2024-01-23
CN107847490A (zh) 2018-03-27
EP3310354A1 (en) 2018-04-25
US20190167643A1 (en) 2019-06-06
AU2024202528B2 (en) 2026-01-08
MA43271A (fr) 2018-09-26
AU2016280280A1 (en) 2018-01-04
WO2016205658A1 (en) 2016-12-22
US20170027911A1 (en) 2017-02-02
US20170296514A1 (en) 2017-10-19
IL256322B (en) 2022-03-01
EP3310354C0 (en) 2026-02-25
AU2024202528A1 (en) 2024-05-09
EP3310354A4 (en) 2018-12-12
CA2989145A1 (en) 2016-12-22
HK1254608A1 (zh) 2019-07-26
JP2018517734A (ja) 2018-07-05
AU2021277731B2 (en) 2024-04-11
CA2989145C (en) 2024-10-29
US10258608B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
AU2021277731B2 (en) Improved formulations of deferasirox and methods of making the same
EP3449911B1 (en) Pharmaceutical formulations
AU2017262586B2 (en) Improved drug formulations
WO2012116238A1 (en) PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
US20220265633A1 (en) Pharmaceutical compositions of cabozantinib
US20250360085A1 (en) Improved drug formulations
US20190015412A1 (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
JP5980449B2 (ja) 非晶質なシロスタゾールを含有する固体分散体
CN107693516B (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
US20250352482A1 (en) Amorphous dosage form containing ebselen
US20250255822A1 (en) Triptolide formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: AUSTINPX, LLC

Free format text: FORMER NAME(S): DISPERSOL TECHNOLOGIES, LLC